#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Another Positive Study of Ovarian Carcinoma


Authors: J. Chovanec
Authors‘ workplace: Oddělení Gynekologické onkologie, MOÚ Brno
Published in: Klin Onkol 2012; 25(5): 386
Category: Oncology Highlights


Sources

1. ÚZIS ČR. NOR ČR. Novotvary 2009 ČR. ÚZIS ČR, NOR ČR 2012. Dostupné z: http://www.uzis.cz/publikace/novotvary-2009.

2. Burger RA, Brady MF, Bookman MA et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473–2483.

3. Perren TJ, Swart AM, Pfisterer J et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26): 2484–2896.

4. Aghajanian C, Finkler NJ, Rutherford T et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). 2012 ASCO Annual Meeting Abstract No: LBA5007.

5. Pujade-Lauraine E. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). 2012 ASCO Annual Meeting Abstract No: LBA5002.

Labels
Paediatric clinical oncology Surgery Clinical oncology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#